Excess mortality in younger patients with myeloproliferative neoplasms

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank the Johns Family Fund of the Cancer Research & Treatment Fund, New York, NY for research support. We thank Ms. Mara Sanderson for technical assistance. This study was presented in part as an oral abstract at the 63rd American Society of Hematology Annual Meeting & Exposition in 2021 (Submitted August 1st, 2021 and delivered December 11th, 2021).

Ethical approval statement: SEER data are de-identified and publicly available, thereby exempt from Institutional Review Board review.

Patient consent statement: not applicable.

Permission to reproduce material from other sources: not applicable.

Clinical trial registration: not applicable.

Authors contributions

Conceptualization and design: KAZ, KS, GAZ. Acquisition, analysis, interpretation of data: all authors. Drafting of the manuscript: all authors. Critical revision of the manuscript for important intellectual content: RTS, JS, GAZ. Statistical analysis: KAZ, KS, GAZ. Supervision: RTS, JS, GAZ.

Disclosure statement

KAZ/KS – none. GAZ – consultancy: PharmaEssentia. Research funding: PharmaEssentia. RTS – consultancy: PharmaEssentia. JS – consultancy: Abbvie. Research funding: Abbvie, Constellation Pharmaceuticals.

Data availability statement

SEER and CDC WONDER databases are publicly available at https://seer.cancer.gov, https://wonder.cdc.gov.

Additional information

Funding

The study was supported by the Johns Family Fund of the Cancer Research & Treatment Fund (CR&T), New York, NY, USA.